Infinitopes Precision Immunomics Raises £12.8M for Cancer Research
Infinitopes Precision Immunomics, an Oxford, UK-based integrated cancer biotech company, recently announced the successful completion of a Seed funding round that raised £12.8M. The funding was led by Octopus Ventures, with participation from various organizations such as Cancer Research Horizons, Cancer Research Institute, and CRIS Cancer Foundation. Additionally, the round saw involvement from investors like Kindred Capital, Manta Ray, and Wilbe Capital, as well as expert angel investors. The primary objective of this funding round is to expedite the installation of LC-MS/MS mass spectrometer equipment, which would enhance the company's proprietary tumour antigen discovery and computational immunobiology/AI/machine learning techniques. This advancement will pave the way for identifying and ranking optimal target combinations to combat five different types of cancers.
Under the leadership of CEO Jonathan Kwok, Infinitopes has successfully amalgamated two key platforms - precision antigen discovery and high-efficiency vector delivery systems - to formulate immunologically durable vaccines capable of targeting multiple solid tumor indications.
The company is set to introduce its lead vaccine candidate into phase I/IIa trials in Q3 2024, imparting considerable optimism within the scientific community. Leveraging its cutting-edge Precision ImmunomicsTM antigen discovery technologies, Infinitopes can pinpoint and prioritize tumor signatures, devoid of any preconceived biases. This unique approach enables the precise selection of novel, synergistic tumor targets, thereby optimizing treatment outcomes. The company's proprietary vector delivery systems are designed to stimulate lasting T-cell responses crucial for impeding the resurgence of life-threatening cancer metastases. ITOP1, the flagship cancer vaccine asset developed by Infinitopes, is slated to undergo phase I/IIa trials targeting first-line cancer patients later in 2024.
Jonathan Kwok, in response to the recent funding announcement, expressed his enthusiasm for the groundbreaking work being undertaken by Infinitopes. Since its establishment in September 2021, the company has been at the forefront of developing a novel class of precision-targeted, enduring cancer vaccines. Kwok highlighted the potential of their therapies to outshine existing blockbuster checkpoint inhibitors and revolutionize cancer treatment paradigms. By identifying the most suitable targets and employing the right vectors for individual patients at the most opportune stage of their treatment journey, Infinitopes aims to deliver unprecedented results. Kwok underscored the importance of collaborations with academic institutions, pharmaceutical giants, and investors in furthering the company's mission to eradicate cancer, while also extending invitations to passionate individuals keen on contributing to this transformative cause.
They've invested in Infinitopes
Get to know these Biotech investors
| # | Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|---|
1 |  Octopus Ventures | 35 investment(s) investment(s) | 30 contacts contacts | |||
2 |  Cancer Research Horizons | 2 investment(s) investment(s) | 9 contacts contacts | |||
3 |  Cancer Research Institute | 1 investment(s) investment(s) | more info | |||
4 |  CRIS Cancer Foundation | 1 investment(s) investment(s) | more info | |||
5 |  Kindred Capital | 9 investment(s) investment(s) | more info |
Click here for a full list of 6,528+ startup investors in the UK